肺腺癌中可变剪接调控因子KHSRP调控的差异剪接基因分析

doi:10.19401/j.cnki.1007-3639.2023.07.001

摘要/Abstract

摘要：

背景与目的：可变剪接在细胞增殖、生长、凋亡及分化等复杂的蛋白质功能调控中发挥着至关重要的作用，能参与包括肿瘤在内的多种疾病的发生、发展过程，目前大多数可变剪接调控因子的功能及其作用机制尚不清楚。本研究旨在探讨KH型剪接调控蛋白（KH-type splicing regulatory protein，KHSRP）在肺腺癌中的差异剪接靶基因及靶基因的表达与患者预后及免疫细胞功能的相关性。方法：通过高通量可变剪接测序，筛选KHSRP下游差异剪接靶基因。通过肿瘤免疫评估资源（Tumor IMmune Estimation Resource，TIMER）和阿拉巴马大学伯明翰分校癌症数据分析门户（the University of Alabama at Birmingham cancer data analysis portal，ULCAN）分析KHSRP下游差异剪接靶基因在肺腺癌中的表达。通过Kaplan数据库分析KHSRP下游差异剪接靶基因的表达与患者预后的相关性。通过TIMER免疫模块分析KHSRP下游差异剪接靶基因与免疫细胞功能的相关性。结果：NUMB、ADD3及LIMCH1为KHSRP的下游关键可变剪接靶基因。NUMB、ADD3及LIMCH1在肺腺癌肿瘤组织中均呈低表达，其低表达者预后不良。NUMB、ADD3及LIMCH1与免疫细胞功能呈正相关。结论：在肺腺癌中，NUMB、ADD3及LIMCH1为KHSRP的差异剪接靶基因，且NUMB、ADD3及LIMCH1低表达会导致预后不良，并且与免疫细胞功能呈正相关。

关键词: 肺腺癌, KH型剪接调控蛋白, 可变剪接, 差异剪接靶基因

Abstract:

Background and purpose: Alternative splicing plays a crucial role in the functions and regulation of complex proteins such as cell proliferation, growth, apoptosis and differentiation, and can cause the occurrence and development of various diseases, including cancer. Currently, the functions and molecular mechanisms of most alternative splicing factors are not clear. The purpose of this study was to explore the differential splicing target genes of KH-type splicing regulatory protein (KHSRP) in lung adenocarcinoma and their correlation with prognosis and immune cell function. Methods: Screening downstream differential splicing target genes of KHSRP was carried out through high-throughput variable splicing sequencing. We analyzed the expressions of KHSRP downstream differential splicing target genes in lung adenocarcinoma through cancer databases Tumor IMmune Estimation Resource (TIMER) and the University of Alabama at Birmingham cancer data analysis portal (ULCAN). We also analyzed the correlation between the expression of differential splicing target genes downstream of KHSRP and prognosis through Kaplan database. The correlation between downstream differential splicing target genes of KHSRP and immune cell function was analyzed through the TIMER immune module. Results: NUMB endocytic adaptor protein (NUMB), adducin 3 (ADD3) and LIM and calponin homology domains 1 (LIMCH1) were key downstream variable splicing target genes of KHSRP. NUMB, ADD3 and LIMCH1 were all expressed at low level in lung adenocarcinoma tumor tissue. Low expressions of NUMB, ADD3 and LIMCH1 in lung cancer leaded to poor prognosis. NUMB, ADD3 and LIMCH1 were positively correlated with immune cell function. Conclusion: In lung adenocarcinoma, NUMB, ADD3 and LIMCH1 are differential splicing target genes of KHSRP, their low expression levels indicate poor prognosis, and they are positively correlated with immune cell function.

Key words: Lung adenocarcinoma, KH-type splicing regulatory protein, Variable splicing, Differential splicing target genes

中图分类号:

R734.2

刘晓丽, 柴文君, 孙磊, 闫明霞, 潘洪玉, 孙跃喜. 肺腺癌中可变剪接调控因子KHSRP调控的差异剪接基因分析[J]. 中国癌症杂志, 2023, 33(7): 637-645.

LIU Xiaoli, CHAI Wenjun, SUN Lei, YAN Mingxia, PAN Hongyu, SUN Yuexi. Analysis of differential splicing gene by regulation of splicing regulatory protein KHSRP in lung adenocarcinoma[J]. China Oncology, 2023, 33(7): 637-645.

图/表 6

图1

图2

图3

图4

图5

图6

参考文献 30

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.v68.6
[2]	TIAN C H, WANG Y, YU H P, et al. A gene expression map of shoot domains reveals regulatory mechanisms[J]. Nat Commun, 2019, 10(1): 141. doi: 10.1038/s41467-018-08083-z pmid: 30635575
[3]	LI M M, WU P D, YANG Z C, et al. miR-193a-5p promotes pancreatic cancer cell metastasis through SRSF6-mediated alternative splicing of OGDHL and ECM1[J]. Am J Cancer Res, 2020, 10(1): 38-59. pmid: 32064152
[4]	JBARA A, LIN K T, STOSSEL C, et al. RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer[J]. Nature, 2023, 617(7959): 147-153. doi: 10.1038/s41586-023-05820-3
[5]	PELLARIN I, DALL’ACQUA A, GAMBELLI A, et al. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity[J]. Oncogene, 2020, 39(22): 4390-4403. doi: 10.1038/s41388-020-1292-6 pmid: 32332923
[6]	HE Y T, OUYANG Z B, LIU W W, et al. TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing[J]. Oncogene, 2023, 42(1): 49-61. doi: 10.1038/s41388-022-02539-9
[7]	HU X H, HARVEY S E, ZHENG R, et al. The RNA-binding protein AKAP8 suppresses tumor metastasis by antagonizing EMT-associated alternative splicing[J]. Nat Commun, 2020, 11(1): 486. doi: 10.1038/s41467-020-14304-1 pmid: 31980632
[8]	YADAV P, PANDEY A, KAKANI P, et al. Hypoxia-induced loss of SRSF2-dependent DNA methylation promotes CTCF-mediated alternative splicing of VEGFA in breast cancer[J]. iScience, 2023, 26(6): 106804. doi: 10.1016/j.isci.2023.106804
[9]	JIA R B, CHAI P W, WANG S Z, et al. m6A modification suppresses ocular melanoma through modulating HINT2 mRNA translation[J]. Mol Cancer, 2019, 18(1): 161. doi: 10.1186/s12943-019-1088-x
[10]	LOBAS A A, SOLOVYEVA E M, LEVITSKY L I, et al. Identification of alternative splicing in proteomes of human melanoma cell lines without RNA sequencing data[J]. Int J Mol Sci, 2023, 24(3): 2466. doi: 10.3390/ijms24032466
[11]	SONG X, WAN X C, HUANG T Z, et al. SRSF3-regulated RNA alternative splicing promotes glioblastoma tumorigenicity by affecting multiple cellular processes[J]. Cancer Res, 2019, 79(20): 5288-5301. doi: 10.1158/0008-5472.CAN-19-1504 pmid: 31462429
[12]	LARIONOVA T D, BASTOLA S, AKSININA T E, et al. Alternative RNA splicing modulates ribosomal composition and determines the spatial phenotype of glioblastoma cells[J]. Nat Cell Biol, 2022, 24(10): 1541-1557. doi: 10.1038/s41556-022-00994-w pmid: 36192632
[13]	KING P H, CHEN C Y. Role of KSRP in control of type Ⅰ interferon and cytokine expression[J]. J Interferon Cytokine Res, 2014, 34(4): 267-274. doi: 10.1089/jir.2013.0143
[14]	BRADLEY R K, ANCZUKÓW O. RNA splicing dysregulation and the hallmarks of cancer[J]. Nat Rev Cancer, 2023, 23(3): 135-155. doi: 10.1038/s41568-022-00541-7 pmid: 36627445
[15]	AGRAWAL A A, YU L, SMITH P G, et al. Targeting splicing abnormalities in cancer[J]. Curr Opin Genet Dev, 2018, 48: 67-74. doi: S0959-437X(17)30088-6 pmid: 29136527
[16]	CLIMENTE-GONZÁLEZ H, PORTA-PARDO E, GODZIK A, et al. The functional impact of alternative splicing in cancer[J]. Cell Rep, 2017, 20(9): 2215-2226. doi: 10.1016/j.celrep.2017.08.012
[17]	YAN M X, SUN L, LI J, et al. RNA-binding protein KHSRP promotes tumor growth and metastasis in non-small cell lung cancer[J]. J Exp Clin Cancer Res, 2019, 38(1): 478. doi: 10.1186/s13046-019-1479-2
[18]	MIN H, TURCK C W, NIKOLIC J M, et al. A new regulatory protein, KSRP, mediates exon inclusion through an intronic splicing enhancer[J]. Genes Dev, 1997, 11(8): 1023-1036. doi: 10.1101/gad.11.8.1023
[19]	BECHARA E G, SEBESTYÉN E, BERNARDIS I, et al. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation[J]. Mol Cell, 2013, 52(5): 720-733. doi: 10.1016/j.molcel.2013.11.010 pmid: 24332178
[20]	WANG J Z, FU X, FANG Z Y, et al. QKI-5 regulates the alternative splicing of cytoskeletal gene ADD3 in lung cancer[J]. J Mol Cell Biol, 2021, 13(5): 347-360. doi: 10.1093/jmcb/mjaa063
[21]	LECHUGA S, AMIN P H, WOLEN A R, et al. Adducins inhibit lung cancer cell migration through mechanisms involving regulation of cell-matrix adhesion and cadherin-11 expression[J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(3): 395-408. doi: 10.1016/j.bbamcr.2018.10.001
[22]	WANG Y B, BAO Y F, ZHANG S R, et al. Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targets[J]. Sci China Life Sci, 2020, 63(4): 469-484. doi: 10.1007/s11427-019-1605-0 pmid: 32086672
[23]	REN P P, LU L Y, CAI S S, et al. Alternative splicing: a new cause and potential therapeutic target in autoimmune disease[J]. Front Immunol, 2021, 12: 713540. doi: 10.3389/fimmu.2021.713540
[24]	PAUCEK R D, BALTIMORE D, LI G D. The cellular immunotherapy revolution: arming the immune system for precision therapy[J]. Trends Immunol, 2019, 40(4): 292-309. doi: S1471-4906(19)30025-0 pmid: 30871979
[25]	LIU Y T, YAN X, ZHANG F, et al. TCR-T immunotherapy: the challenges and solutions[J]. Front Oncol, 2021, 11: 794183. doi: 10.3389/fonc.2021.794183
[26]	SELLARS M C, WU C J, FRITSCH E F. Cancer vaccines: building a bridge over troubled waters[J]. Cell, 2022, 185(15): 2770-2788. doi: 10.1016/j.cell.2022.06.035 pmid: 35835100
[27]	JAYASINGHE R G, CAO S, GAO Q S, et al. Systematic analysis of splice-site-creating mutations in cancer[J]. Cell Rep, 2018, 23(1): 270-281.e3. doi: S2211-1247(18)30397-8 pmid: 29617666
[28]	KAHLES A, LEHMANN K V, TOUSSAINT N C, et al. Comprehensive analysis of alternative splicing across tumors from 8, 705 patients[J]. Cancer Cell, 2018, 34(2): 211-224.e6. doi: 10.1016/j.ccell.2018.07.001
[29]	BURBAGE M, ROCAÑÍN-ARJÓ A, BAUDON B, et al. Epigenetically controlled tumor antigens derived from splice junctions between exons and transposable elements[J]. Sci Immunol, 2023, 8(80): eabm6360. doi: 10.1126/sciimmunol.abm6360
[30]	FRANKIW L, BALTIMORE D, LI G D. Alternative mRNA splicing in cancer immunotherapy[J]. Nat Rev Immunol, 2019, 19(11): 675-687. doi: 10.1038/s41577-019-0195-7 pmid: 31363190